	US 11,814,432 B2
	Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
Li Zhou, West Roxbury, MA (US); Tobias Abel, Antibes (FR); François Meyer, Porrentruy (CH); Megan Levings, Vancouver (CA); Nicolas Dawson, Vancouver (CA); and Caroline Lamarche, Vancouver (CA)
Assigned to The University of British Columbia, Vancouver (CA); and Sangamo Therapeutics France, Valbonne Sophia Antipolis (FR)
Appl. No. 16/649,426
Filed by THE UNIVERSITY OF BRITISH COLUMBIA, Vancouver (CA); and SANGAMO THERAPEUTICS FRANCE, Valbonne Sophia Antipolis (FR)
PCT Filed Sep. 20, 2018, PCT No. PCT/CA2018/051174 § 371(c)(1), (2) Date Mar. 20, 2020, PCT Pub. No. WO2019/056106, PCT Pub. Date Mar. 28, 2019.
Claims priority of provisional application 62/691,027, filed on Jun. 28, 2018.
Claims priority of provisional application 62/560,841, filed on Sep. 20, 2017.
Prior Publication US 2020/0283530 A1, Sep. 10, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); A61K 35/12 (2015.01)

CPC C07K 16/2833 (2013.01) [A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70575 (2013.01); A61K 2035/122 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)]

14 Claims

1. A humanized anti-HLA-A2 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable domain (VH) that comprises the amino acid sequence of SEQ ID NO: 9, and a light chain variable domain (VL) that comprises the amino acid sequence of SEQ ID NO: 13.